Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Patrick K. S. Ng"'
Autor:
Turcin Saridogan, Argun Akcakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott, Bryce P. Kirby, Xiaofeng Zheng, Min Jin Ha, Huiqin Chen, Patrick K. S. Ng, Timothy P. DiPeri, Gordon B. Mills, Jordi Rodon Ahnert, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as therapeutic targets. Futibatinib (TAS-120; Taiho) is a novel, selective, pan-FGFR inhib
Externí odkaz:
https://doaj.org/article/54d8ba5ed19745f68237d1d74ca99a08
Autor:
Carman K. M. Ip, Patrick K. S. Ng, Kang Jin Jeong, S. H. Shao, Zhenlin Ju, P. G. Leonard, Xu Hua, Christopher P. Vellano, Richard Woessner, Nidhi Sahni, Kenneth L. Scott, Gordon B. Mills
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Activation of PDGFRA by genomic aberrations contributes to tumor progression in several tumor types. Here, the authors perform functional characterization of 16 novel PDGFRA mutations identified from different tumor types and demonstrate that a neomo
Externí odkaz:
https://doaj.org/article/5afbb5f4318a4d348864297344880429
Autor:
Carol P Y, Lau, Lin, Huang, Stephen K W, Tsui, Patrick K S, Ng, Pui-Yin, Leung, Shekhar M, Kumta
Publikováno v:
Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 29(3)
Giant cell tumor (GCT) is the most common nonmalignant primary bone tumor reported in Hong Kong. It usually affects young adults between the ages of 20 and 40. This tumor is well known for its potential to recur following treatment. To date no effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::381d216dd94cdf8d9cf287e41bbee2ec
https://pubmed.ncbi.nlm.nih.gov/20886653
https://pubmed.ncbi.nlm.nih.gov/20886653